Nanomedicine-based Chemo-Immunotherapy for the Treatment of Pediatric Brain Cancer

点击翻译按钮获取中文摘要

For this project, we proposed to generate and validate a syngeneic mouse model of medulloblastoma and understand the potential of a tumor pH-sensitive NM loaded with ICD-inducing drug modulating tumor immune environment against MB. Towards these aims, we managed to achieve the following research outcomes-Generate and validate a syngeneic mouse model of medulloblastoma (MB) - Dr. Robert Wechsler-Reya's laboratory at Sanford Burnham Prebys Medical Discovery Institute, CA, United States, established several MB syngeneic models. One of the collaborating investigators (Co-I), Dr. Sabina Quader, could successfully initiate a research collaboration with Dr. Wechsler-Reya. Through this collaboration we created a syngeneic mouse model of MB in our laboratory. We consider this a significant advancement in our MB-related research, as developing a syngeneic mouse model is critical for immune-related studies against MB.Collect preliminary research results using tumor pH-sensitive NM loaded with ICD-inducing drug against MB syngeneic model- We have successfully completed our preliminary research studies using tumor pH-sensitive NM loaded with ICD-inducing drug against MB syngeneic model. Based on the results of these studies, we are now moving on to the next phase of studies, where we are considering examining the potential of using immune checkpoint inhibitors.